CV data added to labels for treatments containing empagliflozin.
Read More »EMPA-REG Outcome Trial, Part 4
In this week's Homerun Slides, the vital stats of patients on the placebo and empagliflozin 10- and 25-gram study.
Read More »Preventing CV Death in Patients With Diabetes
What do we need to tell our patients about preventing the risk for death?
Read More »Dr. Jeffrey Mechanick Part 9, Determining Best Treatment
Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 9 of this Exclusive Interview, Dr. Mechanick reiterates his call for the individualization of diabetes care.
Read More »EMPA-REG Outcome Trial, Part 3
In this week's Homerun Slides, the baseline characteristics of the randomized, placebo-controlled cardiovascular outcome trial of empagliflozin.
Read More »Looking Back: 2016 in SGLT-2 Inhibitors News
2016 in SGLT-2 Inhibitors: saw a host of important information on SGLT-2 inhibitors. Catch up with our best of 2016 articles.
Read More »EMPA-REG Outcome Trial, Part 2
In this week's Homerun Slides, EMPA-REG Outcome, examining the long-term effects of empagliflozin versus using a placebo on the heart and mortality risk in patients with type 2.
Read More »FDA Approves Drug for Reducing CVD Death
The US Food and Drug Administration (FDA) has approved empagliflozin (Jardiance, Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly) for the new indication of improving survival in adults with type 2 diabetes and cardiovascular disease (CVD).
Read More »History and Sequence of Events for the SGLT-2 Inhibitors
2016 could be remembered for the year when the diabetes class of drugs known as the SGLT-2 inhibitors has made a huge impact on the lives of those with type 2 diabetes today and into the future. Never in the history of the treatment for diabetes have we seen a new drug entry that reduce the risk for dying for those with diabetes.
Read More »EMPA-REG Outcome Trial, Part 1
In this week's Homerun Slides: EMPA-REG Outcome Trial Part 1: Meta-analysis of intensive glucose control in T2DM.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.